Legend Biotech (LEGN) could see pressures from competition and its recent leadership change, potentially weighing on its Carvykti myeloma therapy strategy, Oppenheimer said in a Wednesday note.

Chief Executive Ying Huang resigned from the company in July and his departure raised concerns over strategies as Anito-cel nears potential approval and commercialization as a competing myeloma treatment, the investment firm said.

Anito-cel's approval could pressure Legend Biotech's stock and Carvykti's near-term growth, but Oppenheimer noted that it continues to expect Carvykti to corner a majority of the market share in multiple myeloma.

Carvykti sales could still peak at about $5 billion, but its near-term position could depend on the new CEO's strategic vision, the brokerage said.

Oppenheimer downgraded Legend Biotech to perform from outperform and adjusted the price target to $40 from $75.

Price: 20.66, Change: -1.17, Percent Change: -5.36